Key questions answered in Oncology Reimbursement Report 2011-2012
- How oncology therapies will be reimbursed and managed
- Which cancer indication presents the highest cost burden to health plans
- Most-utilized payer management tactics and cost monitoring techniques in oncology
- Which guidelines and evidence recommendations payers follow most
- Impact of Healthcare Reform on oncology
- Which comparative-effectiveness methodologies will have the greatest impact on cost efficient care and drug utilization
- Which aspects of Healthcare Reform will have the greatest impact on oncology management
- Payers’ strategies relative to accountable care organizations and patient-centered medical homes — and the likelihood these entities will be created in significant numbers
- Primary drivers and challenges behind payer creation of ACOs and PCMHs
- Payers’ perceptions of the impact of ACOs and PCMHs on the management of oncology
- Payers’ use of quality initiatives in oncology
- How payers will utilize diagnostics for coverage decisions for targeted therapies
- Which guidelines have the most influence on payers’ decisions for coverage of diagnostics
- Which cancer indication receives the highest reimbursement for genetic tests
- Payers’ perceptions of the primary benefits and drawbacks of genetic testing
- The most common approaches for genetic test coverage
Methodology
Reimbursement Intelligence fielded a survey to 55 medical and pharmacy directors representing top 100 US Commercial and Medicare health plans, covering more than 150 million lives. All respondents are active participants in their plans’ Pharmacy & Therapeutics (P&T) Committees.
Deliverables
A comprehensive PowerPoint presentation. For customers who order the full report, we will also make an in-person presentation.